Disulfiram

證據等級: L5

預測適應症: 0 個

Disulfiram (DB00822): Drug Repurposing Evaluation — Incomplete Data Package

⚠️ Notice: This Evidence Pack contains critical data gaps. The TxGNN model returned no predicted indications, and regulatory, safety, and mechanism-of-action data are absent from the package. This report documents current findings and specifies the remediation steps required before a full repurposing evaluation can be conducted.

One-Sentence Summary

Disulfiram (DrugBank: DB00822) is a well-established aldehyde dehydrogenase (ALDH) inhibitor, classically used for alcohol use disorder (aversion therapy). However, the current Evidence Pack contains no TxGNN-predicted indications, no approved product registrations in Denmark, and no machine-readable safety data, making a standard repurposing evaluation impossible at this stage. A Hold decision is recommended until the blocking data gaps are resolved.

Quick Overview

Item	Content
Original Indication	Alcohol use disorder (aversion therapy) — from general pharmacological knowledge; no structured indication data in this package
Predicted New Indication	Not available — TxGNN returned no predictions for this candidate
TxGNN Prediction Score	Not available
Evidence Level	L5 (model prediction only — and even this is absent; effectively unranked)
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No predicted indication is available in this Evidence Pack, so no mechanistic bridge analysis can be performed at this time.

From established pharmacological knowledge, Disulfiram irreversibly inhibits aldehyde dehydrogenase (ALDH), causing accumulation of acetaldehyde when ethanol is ingested, which produces the disulfiram-ethanol reaction used therapeutically in alcohol aversion therapy. Outside this classical role, ALDH inhibition and secondary copper-chelating activity have attracted research interest in oncology (particularly glioblastoma and breast cancer) and infectious disease contexts — however, none of this is reflected in the current Evidence Pack, and no structured MOA data (DB002 — High severity) is available to formally support such reasoning here.

Once the DrugBank API query is completed and original_moa is populated, a mechanistic analysis can be generated.

Clinical Trial Evidence

No predicted indication is present in this Evidence Pack; therefore, no indication-specific clinical trial evidence can be extracted or tabulated.

Currently no related clinical trials registered under a TxGNN-predicted indication.

Literature Evidence

Currently no related literature available under a TxGNN-predicted indication.

Denmark Market Information

Disulfiram has no marketing authorisations registered in Denmark at the time of this data pull (2026-04-05).

Marketing Authorisation Number	Product Name	Dosage Form	Approved Indication
—	—	—	No authorisations on record

Note: Disulfiram (brand name Antabuse) is registered in several EU member states and has EMA precedent. A separate manual search of the Danish Medicines Agency (Lægemiddelstyrelsen) product register and the EMA centralised database is recommended to confirm whether any parallel imports or exemption-based supplies exist.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

All safety fields in this Evidence Pack carry blocking data gaps:

Key Warnings: Not available (DG001 — Blocking severity). Source: Danish SmPC / Lægemiddelstyrelsen product monograph.
Contraindications: Not available (DG001 — Blocking severity).
Drug–Drug Interactions: Query returned not_found (0 interactions). This likely reflects a query failure rather than the absence of interactions — Disulfiram is known to interact with warfarin, phenytoin, metronidazole, and several other agents.

Until DG001 is resolved, no safety-based prescribing decisions should be made on the basis of this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is structurally incomplete — the TxGNN prediction pipeline returned no candidate indications, and both the regulatory and safety data layers are absent. There is no actionable repurposing signal to evaluate at this stage.

To proceed, the following is needed:

[DG001 — Blocking] Retrieve the Danish SmPC (or EMA SmPC if applicable) for Disulfiram; parse warnings, contraindications, and special precautions. Source: Lægemiddelstyrelsen / EMA product monograph PDF.
[DG002 — High] Query DrugBank API for DB00822 to populate original_moa, pharmacodynamics, and toxicity fields. Source: DrugBank https://go.drugbank.com/drugs/DB00822.
[Prediction Gap — Critical] Investigate why predicted_indications is empty:
- Confirm that Disulfiram (DB00822) is present in the TxGNN knowledge graph node list (data/node.csv).
- Re-run scripts/run_kg_prediction.py with explicit DrugBank ID lookup to verify pipeline completion.
- If the drug is absent from the KG, add it as a seed node and re-predict.
[DDI Gap — High] Re-run the DDI query with alternative drug name variants (e.g., “disulfiram”, “tetraethylthiuram disulfide”) and confirm the not_found status is not a normalisation failure.
[Market Status] Cross-check with Lægemiddelstyrelsen’s online product register and EMA’s EPAR database to confirm zero-authorisation status and identify any compassionate-use or named-patient supply pathways currently active in Denmark.

This report was generated from Evidence Pack TW-DB00822-multi (v4, data cutoff 2026-04-05). Results are for research reference only and do not constitute medical advice. All repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.